Bulevirtide monotherapy safe, well-tolerated in chronic hepatitis D patients

LONDON — Bulevirtide induced a greater combined virologic and biochemical response compared with control at 48 weeks in patients with chronic hepatitis D infection, according to research.“HDV causes the most severe form of chronic viral hepatitis with two-to-three-fold increased risk for mortality compared with HBV mono-infection,” Heiner Wedemeyer, PhD, professor and clinical director of gastroenterology, hepatology and endocrinology at Hannover Medical School in Germany, said at the International Liver Congress. “Achieving HDV viral control or cure of chronic HDV isRead More

Categories: News

Related Articles

A MedMal Storm Is Brewing…

“The edges are cracking but the core remains firm and determined,” is how I recently described the present state of our malpractice insurance market for…

Justin Bouck October 31, 2018

PPIs linked to risk for severe infection, decompensation in patients with cirrhosis

LONDON — Exposure to proton pump inhibitors correlated with an increased risk for severe infection and cirrhosis decompensation among a subset of patients with cirrhosis,…

Vaccines provide stronger immunity against COVID-19 vs. infection in cirrhosis patients

SAN DIEGO — Vaccine-induced immunity correlated with significantly greater protection against COVID-19 compared with infection-induced immunity in patients with cirrhosis, according to results presented at…

Resmetirom ‘has potential to be first medication approved’ for patients with NASH

LONDON — Resmetirom was safe and well tolerated at 100 mg and 80 mg doses in patients with nonalcoholic steatohepatitis, according to late-breaking research presented…

Heavy alcohol use, gene variant heighten risk for HCC, mortality in HBV-related cirrhosis

Patients with cirrhosis who have hepatitis B virus infection and a history of heavy alcohol use are at higher risk for hepatocellular carcinoma and mortality,…